Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression.
antivirals
cirrhosis
disease regression
liver stiffness
nucleos(t)ide analogs
portal hypertension
transient elastography
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
08 Feb 2022
08 Feb 2022
Historique:
received:
14
12
2021
revised:
28
01
2022
accepted:
02
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Nucleos(t)ide analog (NA) treatment for hepatitis B virus (HBV) infection may improve clinically significant portal hypertension (CSPH). Data on hepatic venous pressure gradient (HVPG) and non-invasive tests (NITs) for risk re-stratification in virally suppressed HBV-infected patients with pre-treatment CSPH are limited. We retrospectively included patients with long-term (>12 months) suppression of HBV replication and pre-treatment CSPH (i.e., varices, collaterals on cross-sectional imaging, or ascites). Patients were monitored by on-treatment liver stiffness measurement (LSM) and HVPG assessment. The primary outcome was (further) hepatic decompensation (including liver-related mortality). Forty-two patients ( Patients with HBV-induced CSPH who achieved long-term viral suppression were protected from decompensation, if LSM was <25 kPa. LSM ≥ 25 kPa indicates a persisting risk for decompensation, despite long-term HBV suppression.
Sections du résumé
BACKGROUND
BACKGROUND
Nucleos(t)ide analog (NA) treatment for hepatitis B virus (HBV) infection may improve clinically significant portal hypertension (CSPH). Data on hepatic venous pressure gradient (HVPG) and non-invasive tests (NITs) for risk re-stratification in virally suppressed HBV-infected patients with pre-treatment CSPH are limited.
METHODS
METHODS
We retrospectively included patients with long-term (>12 months) suppression of HBV replication and pre-treatment CSPH (i.e., varices, collaterals on cross-sectional imaging, or ascites). Patients were monitored by on-treatment liver stiffness measurement (LSM) and HVPG assessment. The primary outcome was (further) hepatic decompensation (including liver-related mortality).
RESULTS
RESULTS
Forty-two patients (
CONCLUSIONS
CONCLUSIONS
Patients with HBV-induced CSPH who achieved long-term viral suppression were protected from decompensation, if LSM was <25 kPa. LSM ≥ 25 kPa indicates a persisting risk for decompensation, despite long-term HBV suppression.
Identifiants
pubmed: 35207727
pii: jpm12020239
doi: 10.3390/jpm12020239
pmc: PMC8880497
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Liver Int. 2016 Dec;36(12):1755-1764
pubmed: 27634134
J Hepatol. 2016 Oct;65(4):692-699
pubmed: 27242316
Stat Med. 2013 Dec 30;32(30):5381-97
pubmed: 24027076
Hepatology. 2020 Mar;71(3):1023-1036
pubmed: 31365764
J Hepatol. 2021 Dec 30;:
pubmed: 35120736
J Hepatol. 2015 Apr;62(4):956-67
pubmed: 25595883
J Hepatol. 2009 Sep;51(3):468-74
pubmed: 19616339
J Viral Hepat. 2012 Nov;19(11):801-10
pubmed: 23043387
J Hepatol. 2015 Nov;63(5):1118-25
pubmed: 26100495
J Hepatol. 2021 Apr;74(4):819-828
pubmed: 33075344
N Engl J Med. 2006 Mar 9;354(10):1011-20
pubmed: 16525138
Lancet. 2019 Apr 20;393(10181):1597-1608
pubmed: 30910320
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
J Vis Exp. 2020 Jun 18;(160):
pubmed: 32628153
Nat Rev Gastroenterol Hepatol. 2009 Oct;6(10):573-82
pubmed: 19724251
Clin Liver Dis. 2021 May;25(2):311-326
pubmed: 33838852
J Hepatol. 2020 Dec;73(6):1415-1424
pubmed: 32535060
Lancet. 2013 Feb 9;381(9865):468-75
pubmed: 23234725
N Engl J Med. 2008 Dec 4;359(23):2442-55
pubmed: 19052126
Gut. 2021 Sep;70(9):1758-1767
pubmed: 33199442
Hepatology. 2021 Apr;73(4):1275-1289
pubmed: 32659847
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Clin Gastroenterol Hepatol. 2021 Jul 10;:
pubmed: 34256145
Semin Liver Dis. 2020 Aug;40(3):240-255
pubmed: 32557480